"It's not as if it's treading into a market where there are no other therapies, " says Robert Harrington, of Duke University.

FORBES: Eli Lilly's Big Battle

Orexigen says that it has already convened advisers for the trial including Robert Harrington and Robert Califf, both of Duke, and Steven Nissen, of the Cleveland Clinic.

FORBES: Orexigen Lives Again!

But Robert Harrington, a well-known Duke University Medical Center cardiologist, thought that the good and bad results from the drug made the study neutral, meaning there was no clear benefit from the medicine.

FORBES: AtheroGenics: Promise And Peril